Development of laboratory kits for screening chemicals in the development of a new class of medicines
Ubiquitination is a physiological process whose function is the degradation of undesirable proteins, e.g. denatured, redundant, or otherwise dysfunctional. Relies on &bdquo; labeling proteins intended for degradation in proteosomes with ubiquitine molecules. Proteins from ubiquitine ligase families E3 and E2 enzymes are responsible for attaching ubiquitin molecules to the substrate proteins. Recently, it has been shown that E2 and E3 proteins can be used for &bdquo; labelling ubiquitine of selected proteins by means of appropriately constructed linkers and pedal chemicals (so-called. PROTAC, ProTac technology or inducible protein degradation technology). This technology opens up a wide range of opportunities for the development of new drugs in the form of low molecular compounds, which, by inducing the labelling of certain undesirable proteins, e.g. viral or pathogenic proteins, led to their elimination and cessation of pathogenic processes. At present, pharmaceutical companies are investing huge amounts of resources to develop new ProTac compounds. A major problem limiting the development of technologies for inducible protein degradation is access to rapid, low-cost and high pass tests to detect ProTac active in vitro compounds. In this project, Captor Therapeutics has proposed a high pass, scalable and sensitive fluorescent test that allows for immediate detection of active PROTACs. This test is based on known and proven spectroscopic methods, allows easy adaptation to specific needs and responds to the market needs of the large pharmaceutical industry. “Big Pharma”.